Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
One or two doses of cisplatin in canine osteosarcoma?
Osteosarcomas, often affecting young dogs, still belong to the malignant neoplasias with the poorest prognosis and only a few therapeutic options. The local delivery cisplatin in a biodegradable polymer (after amputation) is one of the newer therapies. Is one treatment enough or are two treatments more effective?

The purpose of this study was to evaluate one versus two doses of local delivery cisplatin in a biodegradable polymer (OPLA-Pt) for the treatment of osteosarcoma (OSA) after amputation in dogs.

Medical records were reviewed retrospectively, and 105 dogs were included in the study; 39% of dogs received one treatment (surgical implantation) of OPLA-Pt and 61% of dogs received two treatments of OPLA-Pt after amputation.

Administration of two doses of OPLA-Pt did not have a significant effect on disease-free interval or survival time compared to one dose.

The anatomic site of the tumour was identified as a prognostic factor, and dogs with proximal humeral OSA had the shortest disease-free interval and survival times.

There was no advantage to giving a second dose of local delivery cisplatin following amputation for the treatment of OSA in dogs.


Source: Mehl, M. L., Seguin, B., Dernell, W. S., Lafferty, M., Kass, P. H. & Withrow, S. J. (2005):
Survival analysis of one versus two treatments of local delivery cisplatin in a biodegradable polymer for canine osteosarcoma. In: Veterinary and Comparative Oncology 3 (2), 81-86.




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Punica granatum associated with hepatotoxicosis in cattlemembers
The ingestion of pomegranates was associated with the deaths of 9 of 35 young cattle; 8 were found dead without any prior clinical signs being noted and 1 animal was observed to be weak with pale‐pink mucous membranes. This case report describes also gross pathological and histopathological signs of the affected cattle and discusses the question which toxic principle was underlying in this case.

  • Toceranib phosphate (Palladia®) in canine gastrointestinal stromal tumorsmembers
  • Radioactive iodine uptake in hyperthyroid cats after rh-TSHmembers
  • Hypoechoic tissue changes in dogs with malignant prostatic lymphomamembers
  • Emphysematous gastritis in dogs and catsmembers
  • Primary pulmonary histiocytic sarcoma in dogsmembers
  • Determining prognosis in canine sepsis members
  • Correlation of plasma and tear glucose, creatinine and urea nitrogen in catsmembers
  • Perineal hernias in dogs - always a bilateral problem?members
  • Pharmacokinetic of gabapentin in catsmembers
  • Follicular development of canine ovaries stimulated by eCG plus hCGmembers
  • Gastrointestinal effects following acupuncture in healthy dogsmembers
  • Bilateral repair of apparently unilateral perineal hernias in dogsmembers


  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved